AGTC Announces Updated Development Plan for its X-Linked Retinitis Pigmentosa Clinical Program, Including Q1 2021 Start of Planned Phase 2/3 Trial
FDA feedback allows for forward program developmentCompany reiterates that its favorable safety profile and its advanced manufacturing and analytics capabilities […]